BACKGROUND/AIMS: This retrospective analysis compared progression-free survival (PFS) in 111 patients who developed or had preexisting hypertension with those who did not during treatment with second-line sunitinib. Secondary objectives included overall survival (OS) and safety. METHODS: Patients with metastatic renal cell carcinoma (mRCC) received sunitinib 50 mg orally once daily in 6-week cycles according to a 4-week on/2-week off treatment schedule. Treatment was continued until disease progression, unacceptable toxicity, withdrawal of consent, or death. Resting blood pressure (BP) was monitored by clinic and home measurements. Hypertension was defined as systolic BP ≥140 and/or diastolic BP ≥90 mm Hg. Subsequent antihypertensive treatment was empirical, depending on the patient. RESULTS: Fifty-four (48.6%) patients experienced elevated BP related to sunitinib. Of these, 10 had preexisting hypertension. Patients who developed hypertension related to sunitinib treatment experienced significantly longer PFS and OS compared to those who did not (p < 0.00001). Patients who required at least 3 antihypertensive drugs had the longest PFS (p = 0.00002) and OS (p = 0.00001). CONCLUSIONS: The development of hypertension during sunitinib treatment was a positive predictive factor associated with a significantly longer PFS and OS in patients with mRCC.
BACKGROUND/AIMS: This retrospective analysis compared progression-free survival (PFS) in 111 patients who developed or had preexisting hypertension with those who did not during treatment with second-line sunitinib. Secondary objectives included overall survival (OS) and safety. METHODS:Patients with metastatic renal cell carcinoma (mRCC) received sunitinib 50 mg orally once daily in 6-week cycles according to a 4-week on/2-week off treatment schedule. Treatment was continued until disease progression, unacceptable toxicity, withdrawal of consent, or death. Resting blood pressure (BP) was monitored by clinic and home measurements. Hypertension was defined as systolic BP ≥140 and/or diastolic BP ≥90 mm Hg. Subsequent antihypertensive treatment was empirical, depending on the patient. RESULTS: Fifty-four (48.6%) patients experienced elevated BP related to sunitinib. Of these, 10 had preexisting hypertension. Patients who developed hypertension related to sunitinib treatment experienced significantly longer PFS and OS compared to those who did not (p < 0.00001). Patients who required at least 3 antihypertensive drugs had the longest PFS (p = 0.00002) and OS (p = 0.00001). CONCLUSIONS: The development of hypertension during sunitinib treatment was a positive predictive factor associated with a significantly longer PFS and OS in patients with mRCC.
Authors: Szymon Darocha; Michał Wilk; Anna Walaszkowska-Czyż; Jarosław Kępski; Rafał Mańczak; Marcin Kurzyna; Adam Torbicki; Sebastian Szmit Journal: In Vivo Date: 2018 Mar-Apr Impact factor: 2.155
Authors: Piotr Rutkowski; Elżbieta Bylina; Anna Klimczak; Tomasz Switaj; Sławomir Falkowski; Jacek Kroc; Iwona Lugowska; Magdalena Brzeskwiniewicz; Wojciech Melerowicz; Czesław Osuch; Ewa Mierzejewska; Kacper Wasielewski; Agnieszka Woźniak; Urszula Grzesiakowska; Zbigniew I Nowecki; Janusz A Siedlecki; Janusz Limon Journal: BMC Cancer Date: 2012-03-22 Impact factor: 4.430
Authors: Seon Ha Baek; Hyunsuk Kim; Jeonghwan Lee; Dong Ki Kim; Kook-Hwan Oh; Yon Su Kim; Jin Suk Han; Tae Min Kim; Se-Hoon Lee; Kwon-Wook Joo Journal: Korean J Intern Med Date: 2014-01-02 Impact factor: 2.884
Authors: Petri Bono; Stephane Oudard; Istvan Bodrogi; Thomas E Hutson; Bernard Escudier; Jean-Pascal Machiels; John A Thompson; Robert A Figlin; Alain Ravaud; Mert Basaran; Camillo Porta; Sergio Bracarda; Thomas Brechenmacher; Chinjune Lin; Maurizio Voi; Viktor Grunwald; Robert J Motzer Journal: Clin Genitourin Cancer Date: 2016-04-27 Impact factor: 2.872